A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Open Access
- 5 December 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 31 (42), 4559-4566
- https://doi.org/10.1038/onc.2011.539
Abstract
Germline variants in the 3′ untranslated region (3′UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3′UTR of the KRAS oncogene, referred to as the KRAS variant, is associated with both cancer risk and altered tumor biology. Here, we test the hypothesis that the KRAS variant can act as a biomarker of outcome in epithelial ovarian cancer (EOC), and investigate the cause of altered outcome in KRAS variant-positive EOC patients. As this variant seems to be associated with tumor biology, we additionally test the hypothesis that this variant can be directly targeted to impact cell survival. EOC patients with complete clinical data were genotyped for the KRAS variant and analyzed for outcome (n=536), response to neoadjuvant chemotherapy (n=125) and platinum resistance (n=306). Outcome was separately analyzed for women with known BRCA mutations (n=79). Gene expression was analyzed on a subset of tumors with available tissue. Cell lines were used to confirm altered sensitivity to chemotherapy associated with the KRAS variant. Finally, the KRAS variant was directly targeted through small-interfering RNA/miRNA oligonucleotides in cell lines and survival was measured. Postmenopausal EOC patients with the KRAS variant were significantly more likely to die of ovarian cancer by multivariate analysis (hazard ratio=1.67, 95% confidence interval: 1.09–2.57, P=0.019, n=279). Perhaps explaining this finding, EOC patients with the KRAS variant were significantly more likely to be platinum resistant (odds ratio=3.18, confidence interval: 1.31–7.72, P=0.0106, n=291). In addition, direct targeting of the KRAS variant led to a significant reduction in EOC cell growth and survival in vitro. These findings confirm the importance of the KRAS variant in EOC, and indicate that the KRAS variant is a biomarker of poor outcome in EOC likely due to platinum resistance. In addition, this study supports the hypothesis that these tumors have continued dependence on such 3′UTR lesions, and that direct targeting may be a viable future treatment approach.This publication has 33 references indexed in Scilit:
- The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical TestingClinical Cancer Research, 2011
- A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysisThe Lancet Oncology, 2011
- Role of microRNAs in ovarian cancer pathogenesis and potential clinical implicationsThe International Journal of Biochemistry & Cell Biology, 2010
- A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer RiskCancer Research, 2010
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancersCarcinogenesis: Integrative Cancer Research, 2009
- A SNP in a let-7 microRNA Complementary Site in the KRAS 3′ Untranslated Region Increases Non–Small Cell Lung Cancer RiskCancer Research, 2008
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2008
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958